LTAC

MD Ranger’s 2022 Report: New Benchmarks Suggest the Growing Scope and Complexity of Physician Transactions at Hospitals and Health Systems

Retrieved on: 
Tuesday, April 26, 2022
Data Management, Health, Technology, Other Technology, Other Health, Internet, Hospital medicine, Neurology, Enhanced Primary Care Case Management Program, Trauma, Intensivist, Water Quality Initiative, ED, Critical care, Database, MD, P75, Hospital, Infection, Organization, Quality, Telehealth, Contract, Physician, LTAC, COVID, FMV, Healthcare, Anesthesia

Benchmarks include ED coverage, medical directorships, administrative services, hospital-based services, medical staff leadership, telemedicine, diagnostic testing, and clinical hourly rates.

Key Points: 
  • Benchmarks include ED coverage, medical directorships, administrative services, hospital-based services, medical staff leadership, telemedicine, diagnostic testing, and clinical hourly rates.
  • Health care providers use MD Rangers benchmarks to set payment rates, document fair market value, and comply with federal Stark and anti-kickback regulations.
  • MD Ranger is used by hundreds of healthcare organizations, including hospitals, health systems, trauma centers, medical groups, LTACs, outpatient providers, and critical access facilities.
  • MD Ranger partners with leading health care provider organizations to simplify the FMV process and document physician transactions efficiently and cost-effectively.

Netsmart Expands the CareFabric Platform to Support Physical Therapy, Rehabilitation and Wellness Providers

Retrieved on: 
Thursday, April 21, 2022
Mental Health, Mobile, Wireless, Technology, Telecommunications, Software, Practice Management, Managed Care, General Health, Health, Data Management, Health, Â, Documentation, Twitter, EMR, IRF, Disability in Canada, Rehabilitation, DPT, YouTube, Serving His Children, Goal, Patient, LinkedIn, Health information management, LTAC, Technology, Therapy, EHR, Laika (EHR testing framework), Solution, PT, Practice management software, Facebook, Practice management, Quality of life, Face, Software as a service, Knowledge, Healthcare, Medicine, Public relations, Service, Software, NetSmart

Netsmart announces the addition of TheraOffice , an industry-leading practice management platform for physical therapy and rehabilitation practices to the Netsmart portfolio.

Key Points: 
  • Netsmart announces the addition of TheraOffice , an industry-leading practice management platform for physical therapy and rehabilitation practices to the Netsmart portfolio.
  • This addition expands the Netsmart CareFabric platform to deliver workflows for therapy providers to better connect to all venues of healthcare.
  • We are thrilled to add a market leader for physical therapy and rehabilitation solutions and truly value the expertise and knowledge the TheraOffice team is bringing to Netsmart.
  • Rehabilitation impacts all of the community-based care settings Netsmart serves including home health, intellectual and developmental disabilities, inpatient rehabilitation facilities (IRFs), long-term acute care (LTAC) and more.

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

Retrieved on: 
Monday, March 28, 2022
Company, Biomarker, Form 10-K, NASDAQ, Record, Regulatory affairs, Leadership, Worcester Polytechnic Institute, Forward-looking statement, Quality assurance, HIV disease progression rates, Patient, Compliance, Quality, Mechanical, LTAC, U.S. Securities and Exchange Commission, Administration, Harvard University, Management control system, Security (finance), Documentation, Health, Industry, Triage, Program, GLOBE, Technological innovation, Clinical trial, FDA, Fresenius Medical Care, Symphony, Pharmaceutical industry, Medical device, Marketing, Northeastern University, Science, Regulation, Blue jay

ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (Bluejay, the Company) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin Ed E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance.

Key Points: 
  • ACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (Bluejay, the Company) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Edwin Ed E. Rule, has joined the Company as Vice President Regulatory, Quality and Compliance.
  • Mr. Rule is a highly credentialed regulatory, quality and compliance professional with more than 15 years of industry experience.
  • Mr. Rule will be responsible for Bluejays Regulatory, Quality and Compliance functions and will provide support to the Symphony System product development team.
  • Edwin Rule, Vice President of Regulatory, Quality and Compliance of Bluejay Diagnostics, said, I have dedicated my career to helping to bring important, new medical devices to patients by developing constructive regulatory strategies and quality systems to ensure the production of high quality, compliant products.

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Retrieved on: 
Thursday, March 24, 2022
Company, Biomarker, Isenberg School of Management, Form 10-K, NASDAQ, McLaughlin, CPAS, Emirates Institute for Banking and Financial Studies, Forward-looking statement, HIV disease progression rates, Patient, CFO, Savings bank, East Boston Savings Bank, LTAC, U.S. Securities and Exchange Commission, Treasurer, Security (finance), Health, Business administration, University of Massachusetts Medical School, Southern New England School of Law, Rockland Trust, Triage, GLOBE, CPA, IL-6, Certified Public Accountant, Accounting, Parent, University, Symphony, Pharmaceutical industry, Management, Hospital, Blue jay

ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (Bluejay, the Company), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Kenneth Fisher, CPA, has joined the Company as Chief Financial Officer (CFO), effective March 23, 2022.

Key Points: 
  • ACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (Bluejay, the Company), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced that Kenneth Fisher, CPA, has joined the Company as Chief Financial Officer (CFO), effective March 23, 2022.
  • Mr. Fisher is an accomplished financial professional and Certified Public Accountant.
  • Kenneth Fisher, CFO of Bluejay Diagnostics, said, I am excited to join Bluejay at such a pivotal time for the Company.
  • Most recently, he was Executive Vice President, Chief Financial Officer and Treasurer of Meridian Bancorp, Inc. and its subsidiary, East Boston Savings Bank (merged with Rockland Trust in November 2021).

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 10, 2022
IPO, U.S. Securities and Exchange Commission, Acacia, Health, Accounting, Hospital, Net, HIV disease progression rates, Emergency Use Authorization, Program, Net operating loss, Safety, Biomarker, Initial public offering, Company, Marketing, Immune system, Infection, FDA, Director, EUA, GLOBE, Patient, IL-6, NASDAQ, Cancer, Security (finance), Blue jay, Triage, Forward-looking statement, Prudential Financial, Novartis, Inflammation, Research, Form 10-K, Board, Symphony, Interleukin 6, Home After Three Months Away, Harvard Medical School, LTAC, Medical device, Pharmaceutical industry, Risk management, Lithium, Brigham, Gentium

ACTON, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease progression, today announced financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update, including on the Company’s first product candidate, the IL-6 Test.

Key Points: 
  • Bluejay is conducting a comprehensive clinical testing program for its IL-6 Test product candidate.
  • Financial Results for the Three Months Ended December 31, 2021 and Full Year 2021
    Cash and cash equivalents.
  • The Net loss and Net loss per share for 2021 was $3,488,298 and $0.41 compared to $1,158,285 and $0.37 for 2020.
  • The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise.

New Research Finds Long-Term Acute Care Hospitals Can Serve as Meaningful Contributors to Value-Based Care Models

Retrieved on: 
Tuesday, February 22, 2022
Kindred, Partnership, Medicare, Population, Acos, Heart, ACO, COVID-19, Organization, LTAC, Multimedia, Sepsis, FFS, Ageing, Patient, Private sector, ATI, Research, Hospital, Health insurance

The preliminary findings from this case study suggest that value-based models that utilize LTAC hospitals can experience improved beneficiary outcomes and savings in the post-discharge period, largely due to reduced readmission spending.

Key Points: 
  • The preliminary findings from this case study suggest that value-based models that utilize LTAC hospitals can experience improved beneficiary outcomes and savings in the post-discharge period, largely due to reduced readmission spending.
  • Furthermore, Medicare FFS beneficiaries who received care at Kindred LTAC hospitals had nearly 50 percent lower readmission spending after discharge from the initial LTAC hospital stay compared to other LTAC hospitals in Las Vegas.
  • Prior ATI research indicated that LTAC hospitals have provided strong clinical capabilities and an essential safety net for healthcare delivery systems during the COVID-19 Public Health Emergency.
  • ATI Advisory is a research and advisory services firm working to transform the delivery of healthcare and aging services for older adults.

San Diego Habitat Conservancy: Land Trust Accreditation Renewal

Retrieved on: 
Tuesday, February 1, 2022
LTAC, Love, SDHC, Accreditation, SAN, Education, Natural Resources, Knowledge, Forestry

SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- We are excited to share with you that the San Diego Habitat Conservancy (SDHC) land trust accreditation with the Land Trust Accreditation Commission (LTAC) has been renewed!

Key Points: 
  • SAN DIEGO, Feb. 1, 2022 /PRNewswire/ -- We are excited to share with you that the San Diego Habitat Conservancy (SDHC) land trust accreditation with the Land Trust Accreditation Commission (LTAC) has been renewed!
  • There are over 450 accredited land trusts across the country, and we are proud to work within San Diego and the surrounding communities to protect the naturalhabitats we love.
  • SDHC, established in 2000, was the first accredited land trust headquartered in San Diego County.
  • Managing 33 open space preserves throughout the San Diego region, SDHC conserves and manages sensitive habitat and species that are unique to our southern California environment.

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Retrieved on: 
Monday, January 31, 2022
LTAC, Infection, Symphony, Safety, Forward-looking statement, ELISA, Patient, Immune system, Food, NASDAQ, Health, HIV disease progression rates, Nanotechnology, Inflammation, Triage, IL-6, Marketing, Cancer, U.S. Securities and Exchange Commission, Biomarker, Company, Microfluidics, GLOBE, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Comment, FDA, Security (finance), Review, Blue jay, Pharmaceutical industry, Toray Industries

The pre-submission package will allow the FDA to review and comment on the Companys plans for clinical trials and analytical testing.

Key Points: 
  • The pre-submission package will allow the FDA to review and comment on the Companys plans for clinical trials and analytical testing.
  • Neil Dey, Bluejays Chief Executive Officer commented, I am very pleased to announce that Bluejay successfully met its goal of filing the pre-submission package with the FDA for the Symphony IL-6 Test by the end of January, 2022.
  • The pre-submission filing an important milestone for Bluejay as we will receive important feedback from the FDA for our planned marketing submission for the Symphony IL-6 Test, planned for Q3:22.
  • The Symphony IL-6 Test (Symphony IL-6 Test) is currently Bluejays lead product candidate.

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Retrieved on: 
Thursday, January 13, 2022
Storm, Biomarker, Critical care, Blue jay, Trial of the century, Patient, Forward-looking statement, Human, Microfluidics, Inflammation, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, COVID-19, NASDAQ, Nanotechnology, HIV disease progression rates, IL-6, GLOBE, Health, U.S. Securities and Exchange Commission, Electric Bond and Share Company v. Securities and Exchange Commission, Triage, Sepsis, Prognosis, Company, Cancer, Immune system, Symphony, LTAC, Infection, FDA, ELISA, Security (finance), University, Pharmaceutical industry, Medical device, Risk management, Toray Industries

This study performs unique rapid on-site measurement using patient whole blood and positions the Company to move forward with multiple initiatives.

Key Points: 
  • This study performs unique rapid on-site measurement using patient whole blood and positions the Company to move forward with multiple initiatives.
  • Furthermore, using IL-6 as an early warning indicator can assist healthcare systems to sequester critical resources in time to save lives.
  • These studies mark the first of their type, in which IL-6 is quantified directly from the whole blood of COVID-19 (SARS-CoV-2 positive) patients in critical care.
  • The results from this multicenter study are currently being prepared for submission for scientific peer review and publication in the Q3:22 timeframe.

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

Retrieved on: 
Thursday, December 16, 2021
Initial public offering, ELISA, Board, Clinical trial, NASDAQ, EUA, Inflammation, Emergency Use Authorization, Net, Accounting, Forward-looking statement, FDA, Research, Diagnosis, U.S. Securities and Exchange Commission, Cash, LTAC, Sepsis, Prudential Financial, IL-6, Security (finance), Program, GLOBE, Teaching hospital, Acacia, State Administrative Expenses, IPO, Triage, Cancer, CEO, Microfluidics, Infection, Nanotechnology, Company, HIV disease progression rates, Home After Three Months Away, Parkland Memorial Hospital, Interleukin 6, Novartis, University of Texas Southwestern Medical Center, Immune system, Security, Blue jay, University, Medical device, Pharmaceutical industry, Cryptocurrency, Toray Industries, Gentium

ACTON, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”) a late-stage, pre-revenue diagnostics/medical device company focused on developing cost-effective, rapid, near-patient products for triage, diagnosis and monitoring of disease progression, today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update on the Company’s first product candidate, the IL-6 test for sepsis triage.

Key Points: 
  • Bluejay has made substantial progress since our S-1 filing in July 2021.
  • Results from this program will form the basis of the FDA Pre-Submission application expected to be filed in January 2022.
  • Bluejay plans to conduct an expanded clinical testing program for its IL-6 test for sepsis triage product candidate.
  • On November 10, 2021, Bluejay announced the pricing of an upsized $21.6 million underwritten Initial Public Offering of 2,160,000 units, at a unit price of $10.00.